14,975 Shares in Immunocore Holdings PLC Sponsored ADR $IMCR Acquired by Quadrature Capital Ltd

Quadrature Capital Ltd purchased a new stake in shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 14,975 shares of the company’s stock, valued at approximately $471,000.

Several other institutional investors also recently bought and sold shares of the business. Assetmark Inc. increased its position in shares of Immunocore by 3.7% in the second quarter. Assetmark Inc. now owns 34,958 shares of the company’s stock worth $1,097,000 after acquiring an additional 1,248 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in Immunocore by 4,696.3% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 1,295 shares of the company’s stock valued at $41,000 after purchasing an additional 1,268 shares in the last quarter. Elevation Point Wealth Partners LLC purchased a new position in Immunocore in the second quarter valued at about $42,000. Persistent Asset Partners Ltd lifted its stake in shares of Immunocore by 7.6% during the second quarter. Persistent Asset Partners Ltd now owns 24,038 shares of the company’s stock worth $754,000 after purchasing an additional 1,708 shares in the last quarter. Finally, XTX Topco Ltd lifted its stake in shares of Immunocore by 14.7% during the second quarter. XTX Topco Ltd now owns 20,873 shares of the company’s stock worth $655,000 after purchasing an additional 2,681 shares in the last quarter. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

Immunocore Stock Performance

Shares of IMCR opened at $36.17 on Wednesday. The firm has a market cap of $1.83 billion, a price-to-earnings ratio of -63.46 and a beta of 0.77. The company has a quick ratio of 5.97, a current ratio of 6.00 and a debt-to-equity ratio of 0.99. The business’s 50 day moving average is $34.86 and its two-hundred day moving average is $34.16. Immunocore Holdings PLC Sponsored ADR has a 52-week low of $23.15 and a 52-week high of $40.53.

Immunocore (NASDAQ:IMCR) last released its quarterly earnings results on Thursday, November 6th. The company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.32. The business had revenue of $103.69 million during the quarter, compared to the consensus estimate of $137.29 million. Immunocore had a negative net margin of 7.70% and a negative return on equity of 7.67%. The business’s quarterly revenue was up 29.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.17 earnings per share. Analysts forecast that Immunocore Holdings PLC Sponsored ADR will post -0.94 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider David M. Berman sold 22,532 shares of the business’s stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $35.67, for a total value of $803,716.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.40% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Morgan Stanley increased their target price on Immunocore from $34.00 to $36.00 and gave the company an “equal weight” rating in a research note on Monday, November 10th. Wall Street Zen upgraded Immunocore from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunocore in a research note on Wednesday, October 8th. Jefferies Financial Group initiated coverage on shares of Immunocore in a research report on Monday, August 25th. They set a “buy” rating and a $48.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $100.00 price target on shares of Immunocore in a report on Wednesday, October 22nd. Seven analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $61.00.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.